Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.
Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C. Fløtten Ø, et al. Among authors: sundstrom s. Br J Cancer. 2012 Jul 24;107(3):442-7. doi: 10.1038/bjc.2012.284. Epub 2012 Jul 3. Br J Cancer. 2012. PMID: 22759880 Free PMC article. Clinical Trial.
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM; Norwegian Lung Cancer Study Group. Helbekkmo N, et al. Among authors: sundstrom sh. Br J Cancer. 2007 Aug 6;97(3):283-9. doi: 10.1038/sj.bjc.6603869. Epub 2007 Jun 26. Br J Cancer. 2007. PMID: 17595658 Free PMC article. Clinical Trial.
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.
Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U. Strøm HH, et al. Among authors: sundstrom sh. Br J Cancer. 2013 Sep 17;109(6):1467-75. doi: 10.1038/bjc.2013.466. Epub 2013 Aug 20. Br J Cancer. 2013. PMID: 23963145 Free PMC article. Clinical Trial.
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Grønberg BH, et al. Among authors: sundstrom s. J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433683 Clinical Trial.
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten O, Amundsen T, Hjelde HH, Plessen Cv, Jordhøy M. Grønberg BH, et al. Among authors: sundstrom s. Eur J Cancer. 2010 Aug;46(12):2225-34. doi: 10.1016/j.ejca.2010.04.009. Epub 2010 May 12. Eur J Cancer. 2010. PMID: 20471248 Clinical Trial.
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, Stephens R, Vilsvik J, Aasebo U, Sorenson S. von Plessen C, et al. Among authors: sundstrom s. Br J Cancer. 2006 Oct 23;95(8):966-73. doi: 10.1038/sj.bjc.6603383. Epub 2006 Oct 3. Br J Cancer. 2006. PMID: 17047644 Free PMC article. Clinical Trial.
125 results